EGFR and cancer: Increasing evidence suggests that 6-shogaol treatment induces anti-cancer effects via blocking of the EGFR pathway, and EGFR-TKI gefitinib also exerts powerful anti-cancer effects by inhibiting the phosphorylation of EGFR and by activating the ER stress response.